PURPOSE: One of the most important issues to address when developing an optimal screening system for prostate cancer is investigating appropriate biopsy indications following serum prostate-specific antigen (PSA) measurements in order to maintain high sensitivity and avoid unnecessary biopsy. METHODS: Between April 2004 and December 2007, 239 consecutive men with total PSA levels of 2.0-10.0 ng/mL underwent measurements of PSA, free PSA, and [-2]pro-PSA. We assessed the significance of laboratory-based PSA-related indices including free PSA/total PSA (%f-PSA), p2PSA/free PSA (%p2PSA), p2PSA/%f-PSA, Prostate Health Index (phi, an index combining PSA, free PSA, and p2PSA), total prostate volume (TPV)-adjusted PSA-related indices, including PSA density, %p2PSA density, p2PSA/%f-PSA density, and phi density, and transition zone (TZ) prostate volume-adjusted PSA-related indices such as PSA TZ density (PSATZD), %p2PSA TZD, p2PSA/%fPSA TZD, and phi TZD. RESULTS: The positive biopsy rate was 22.2%. When sensitivity was fixed at 95 %, unnecessary biopsies could be avoided in 28% of men when phi was used as a biopsy indication. In cases where total and transition zone prostate volumes were available, the use of %p2PSA density, phi density, p2PSA/%f-PSA TZD, and phi TZD resulted in the avoidance of 48, 47, 54, and 54 % of unnecessary biopsies, respectively, while maintaining a high sensitivity of 90%. CONCLUSIONS: At 90 and 95 % sensitivity, laboratory-based indices containing p2PSA, particularly phi, showed significantly greater specificity for prostate cancer as compared with %f-PSA. The diagnostic accuracy of prostate volume-adjusted p2PSA-related indices could be excellent, particularly the transition zone volume-adjusted indices at fixed sensitivities of 95 and 90%.
PURPOSE: One of the most important issues to address when developing an optimal screening system for prostate cancer is investigating appropriate biopsy indications following serum prostate-specific antigen (PSA) measurements in order to maintain high sensitivity and avoid unnecessary biopsy. METHODS: Between April 2004 and December 2007, 239 consecutive men with total PSA levels of 2.0-10.0 ng/mL underwent measurements of PSA, free PSA, and [-2]pro-PSA. We assessed the significance of laboratory-based PSA-related indices including free PSA/total PSA (%f-PSA), p2PSA/free PSA (%p2PSA), p2PSA/%f-PSA, Prostate Health Index (phi, an index combining PSA, free PSA, and p2PSA), total prostate volume (TPV)-adjusted PSA-related indices, including PSA density, %p2PSA density, p2PSA/%f-PSA density, and phi density, and transition zone (TZ) prostate volume-adjusted PSA-related indices such as PSA TZ density (PSATZD), %p2PSA TZD, p2PSA/%fPSA TZD, and phi TZD. RESULTS: The positive biopsy rate was 22.2%. When sensitivity was fixed at 95 %, unnecessary biopsies could be avoided in 28% of men when phi was used as a biopsy indication. In cases where total and transition zone prostate volumes were available, the use of %p2PSA density, phi density, p2PSA/%f-PSA TZD, and phi TZD resulted in the avoidance of 48, 47, 54, and 54 % of unnecessary biopsies, respectively, while maintaining a high sensitivity of 90%. CONCLUSIONS: At 90 and 95 % sensitivity, laboratory-based indices containing p2PSA, particularly phi, showed significantly greater specificity for prostate cancer as compared with %f-PSA. The diagnostic accuracy of prostate volume-adjusted p2PSA-related indices could be excellent, particularly the transition zone volume-adjusted indices at fixed sensitivities of 95 and 90%.
Authors: Brian V Le; Christopher R Griffin; Stacy Loeb; Gustavo F Carvalhal; Donghui Kan; Nikola A Baumann; William J Catalona Journal: J Urol Date: 2010-02-19 Impact factor: 7.450
Authors: Carsten Stephan; Hellmuth-Alexander Meyer; Maciej Kwiatkowski; Franz Recker; Henning Cammann; Stefan A Loening; Klaus Jung; Michael Lein Journal: Eur Urol Date: 2006-05-02 Impact factor: 20.096
Authors: Theresa Y Chan; Stephen D Mikolajczyk; Kristin Lecksell; Matthew J Shue; Harry G Rittenhouse; Alan W Partin; Jonathan I Epstein Journal: Urology Date: 2003-07 Impact factor: 2.649
Authors: Carsten Stephan; Anna-Maria Kahrs; Henning Cammann; Michael Lein; Mark Schrader; Serdar Deger; Kurt Miller; Klaus Jung Journal: Prostate Date: 2009-02-01 Impact factor: 4.104
Authors: William J Catalona; Georg Bartsch; Harry G Rittenhouse; Cindy L Evans; Harry J Linton; Wolfgang Horninger; Helmut Klocker; Stephen D Mikolajczyk Journal: J Urol Date: 2004-06 Impact factor: 7.450
Authors: William J Catalona; Jerome P Richie; Frederick R Ahmann; M'Liss A Hudson; Peter T Scardino; Robert C Flanigan; Jean B DeKernion; Timothy L Ratliff; Louis R Kavoussi; Bruce L Dalkin; W Bedford Waters; Michael T MacFarlane; Paula C Southwick Journal: J Urol Date: 1994-05 Impact factor: 7.450
Authors: Stacy Loeb; Martin G Sanda; Dennis L Broyles; Sanghyuk S Shin; Chris H Bangma; John T Wei; Alan W Partin; George G Klee; Kevin M Slawin; Leonard S Marks; Ron H N van Schaik; Daniel W Chan; Lori J Sokoll; Amabelle B Cruz; Isaac A Mizrahi; William J Catalona Journal: J Urol Date: 2014-11-15 Impact factor: 7.450
Authors: Alberto Abrate; Giovanni Lughezzani; Giulio Maria Gadda; Giuliana Lista; Ella Kinzikeeva; Nicola Fossati; Alessandro Larcher; Paolo Dell'Oglio; Francesco Mistretta; Nicolòmaria Buffi; Giorgio Guazzoni; Massimo Lazzeri Journal: Korean J Urol Date: 2014-07-11